Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Non-revolving loan
Quarterly results
Director departure
|
|
GT Biopharma, Inc. (GTBP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/22/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/15/2023 |
4
| Breen Michael Martin (Executive Chairman/Interim CEO) has filed a Form 4 on GT Biopharma, Inc.|
Txns:
| Granted 200,000 shares
@ $0.287, valued at
$57.4k
|
|
| 08/15/2023 |
4
| Ohri Manu (CFO & Secretary) has filed a Form 4 on GT Biopharma, Inc.|
Txns:
| Granted 200,000 shares
@ $0.287, valued at
$57.4k
Disposed of 200,000 shares
@ $0.287, valued at
$57.4k
Acquired 200,000 shares
@ $0.287, valued at
$57.4k
|
|
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/05/2023 |
8-K
| Quarterly results |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/05/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 05/04/2023 |
3
| CASAMENTO CHARLES J (Director) has filed a Form 3 on GT Biopharma, Inc. |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/28/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in GT BIOPHARMA, INC. |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"COMMON STOCK PURCHASE WARRANT GT Biopharma, Inc. Warrant No.: _______ Warrant Shares: _______ Initial Exercise Date: July ___, 2023 Issue Date: January ___, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July ____, 2023 and on or prior to 5:00 p.m. on July ____, 2028 1 but not thereafter, to subscribe for and purchase from GT Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise d...",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT GT Biopharma, Inc. Warrant No.: _______ Warrant Shares: _______ Initial Exercise Date: January ___, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from GT Biopharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined here...",
"Form of Placement Agent Warrant",
"Opinion of Baker & McKenzie LLP",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of December ____, 2022, between GT Biopharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser..." |
|
| 12/13/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/13/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 10/12/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 10/04/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/04/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"GT Biopharma Announces Adjournment of Special Shareholders Meeting - Meeting adjourned to October 10, 2022 at 11 a.m. PST - GTB encourages all stockholders of record on August 8, 2022 who have not yet voted - to do so by 11:59 p.m. PST Time on October 9, 2022 BRISBANE, CALIFORNIA, October 4, 2022 /PRNewswire/ — GT Biopharma, Inc. , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’ s proprietary natural killer cell engager, TriKE® platform, today announced that its 2022 Special Shareholders Meeting has been adjourned to October 10, 2022 at 11 a.m. PST due to lack of quorum for its previously scheduled meeting. The adjournment provides the Company with additional time to solicit the necessary proxies from its shareholders to achieve ..." |
|
| 08/30/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/17/2022 |
8-K/A
| Quarterly results |
| 08/17/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/25/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 07/19/2022 |
4
| Breen Michael Martin (Exec. Chair. and Interim CEO) has filed a Form 4 on GT Biopharma, Inc.|
Txns:
| Granted 278,058 shares
@ $0
Granted 50,000 options to buy
@ $2.48, valued at
$124k
|
|
| 07/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2022 |
4
| URBAN ALAN LOUIS (Director) has filed a Form 4 on GT Biopharma, Inc.|
Txns:
| Granted 50,000 options to buy
@ $2.48, valued at
$124k
|
|
|
|
|